The main reason for the downturn in Moderna’s stock is a significant drop in the demand for its COVID-19 vaccine.

The recent downturn in biotech has battered Massachusetts’ world-renowned sector, and the political climate has only made it ...

Barclays Speaking the Science Call Series, on Monday, June 16 th at 10:00am ET A live webcast of this presentation will be available under "Events and Presentations" in the Investors section of the ...

The Food and Drug Administration (FDA) has approved Moderna’s next-generation mRNA COVID-19 vaccine mNexspike ®.

The current fear is that bird flu, H5N1, will become the next big pandemic. Only the mRNA platform is nimble enough to ...

(HealthDay News) — The U.S. Food and Drug Administration has approved a new lower-dose vaccine for active immunization against COVID-19 caused by severe acute respiratory syndrome coronavirus 2.

The second of this two-part article explores what organizations should consider when trying to optimize a mixed team of ...

The number of changes to vaccine policy in the United States in recent weeks is dizzying — and we’ve just hit Code Red.

The Trump administration's cancellation of $766 million in contracts to develop mRNA vaccines against potential pandemic flu ...

Despite positive results from a Phase I/II trial of its investigational pandemic influenza vaccine, mRNA-1018, Moderna’s ...

While the news isn’t great for vaccine manufacturers, it could have been worse. Shares of pure vaccine play Moderna rose 0.3% ...

On Monday, the U.S. Secretary of Health and Human Services, Robert F. Kennedy Jr., decided to fire all 17 members of the ...